- Home
- INVH vs IKT Comparison
INVH vs IKT Comparison
Compare INVH & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | IKT |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 201.3M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INVH | IKT |
|---|---|---|
| Price | $27.88 | $2.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $34.90 | $6.00 |
| AVG Volume (30 Days) | ★ 5.2M | 606.6K |
| Earning Date | 10-29-2025 | 11-14-2025 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | ★ 32.35 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $2,689,621,000.00 | N/A |
| Revenue This Year | $5.69 | N/A |
| Revenue Next Year | $3.21 | N/A |
| P/E Ratio | $29.25 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $26.02 | $1.33 |
| 52 Week High | $35.80 | $3.49 |
Technical Indicators
Market Signals| Indicator | INVH | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 70.97 |
| Support Level | $26.72 | $1.56 |
| Resistance Level | $27.48 | $2.15 |
| Average True Range (ATR) | 0.41 | 0.17 |
| MACD | 0.16 | 0.05 |
| Stochastic Oscillator | 89.67 | 82.85 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.